260 related articles for article (PubMed ID: 35955624)
1. Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.
Xu L; Shao F; Luo T; Li Q; Tan D; Tan Y
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955624
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma.
Wang L; He S; Tu Y; Ji P; Zong J; Zhang J; Feng F; Zhao J; Gao G; Zhang Y
J Clin Neurosci; 2013 Jul; 20(7):958-63. PubMed ID: 23707602
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer Analysis Identifies AIMP2 as a Potential Biomarker for Breast Cancer.
Qiu J; Zhou T; Wang D; Hong W; Qian D; Meng X; Liu X
Curr Genomics; 2023 Dec; 24(5):307-329. PubMed ID: 38235352
[TBL] [Abstract][Full Text] [Related]
5. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.
Wu X; Zhu Z; Li W; Fu X; Su D; Fu L; Zhang Z; Luo A; Sun X; Fu L; Dong JT
Breast Cancer Res; 2012 May; 14(3):R73. PubMed ID: 22569290
[TBL] [Abstract][Full Text] [Related]
6. MiR‑500a‑5p promotes glioblastoma cell proliferation, migration and invasion by targeting chromodomain helicase DNA binding protein 5.
Liu Z; Su D; Qi X; Ma J
Mol Med Rep; 2018 Sep; 18(3):2689-2696. PubMed ID: 30015879
[TBL] [Abstract][Full Text] [Related]
7. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.
Garcia I; Mayol G; Rodríguez E; Suñol M; Gershon TR; Ríos J; Cheung NK; Kieran MW; George RE; Perez-Atayde AR; Casala C; Galván P; de Torres C; Mora J; Lavarino C
Mol Cancer; 2010 Oct; 9():277. PubMed ID: 20950435
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of the Prognostic and Immunological Role of SMG5: A Biomarker for Cancers.
Yang L; Wei J; Ma X; Cheng R; Zhang H; Jin T
Oncology; 2024; 102(2):168-182. PubMed ID: 37699361
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma.
Du X; Wu T; Lu J; Zang L; Song N; Yang T; Zhao H; Wang S
Clin Transl Oncol; 2013 Mar; 15(3):198-204. PubMed ID: 22855185
[TBL] [Abstract][Full Text] [Related]
10. The role of APOBEC3C in modulating the tumor microenvironment and stemness properties of glioma: evidence from pancancer analysis.
Zhang S; Guo Y; Hu Y; Gao X; Bai F; Ding Q; Hou K; Wang Z; Sun X; Zhao H; Qu Z; Xu Q
Front Immunol; 2023; 14():1242972. PubMed ID: 37809064
[TBL] [Abstract][Full Text] [Related]
11. Chromodomain Helicase DNA-Binding Protein 5 Inhibits Renal Cell Carcinoma Tumorigenesis by Activation of the p53 and RB Pathways.
Huang S; Yan Q; Xiong S; Peng Y; Zhao R; Liu C
Biomed Res Int; 2020; 2020():5425612. PubMed ID: 33062682
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma.
Higashi M; Kolla V; Iyer R; Naraparaju K; Zhuang T; Kolla S; Brodeur GM
Mol Cancer; 2015 Aug; 14():150. PubMed ID: 26245651
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5.
Cai C; Ashktorab H; Pang X; Zhao Y; Sha W; Liu Y; Gu X
PLoS One; 2012; 7(1):e29750. PubMed ID: 22235338
[TBL] [Abstract][Full Text] [Related]
15. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
Hall WA; Petrova AV; Colbert LE; Hardy CW; Fisher SB; Saka B; Shelton JW; Warren MD; Pantazides BG; Gandhi K; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Volkan Adsay N; Curran WJ; Landry JC; Maithel SK; Yu DS
Oncogene; 2014 Nov; 33(47):5450-6. PubMed ID: 24276239
[TBL] [Abstract][Full Text] [Related]
16. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
17. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
18. Role of CHD5 in human cancers: 10 years later.
Kolla V; Zhuang T; Higashi M; Naraparaju K; Brodeur GM
Cancer Res; 2014 Feb; 74(3):652-8. PubMed ID: 24419087
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analysis reveals NUP37 as a prognostic biomarker correlated with the immunosuppressive microenvironment in glioma.
He Y; Li J; Shen L; Zhou H; Fei W; Zhang G; Li Z; Wang F; Wen Y
Aging (Albany NY); 2022 Jan; 14(2):1033-1047. PubMed ID: 35093934
[TBL] [Abstract][Full Text] [Related]
20. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma.
Wang J; Chen H; Fu S; Xu ZM; Sun KL; Fu WN
Oral Oncol; 2011 Jul; 47(7):601-8. PubMed ID: 21636313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
